For two days in late July, a federal advisory panel sat in a room in Silver Spring, Maryland and went through seven peptides one by one.

BPC-157 was on the list. The condition they reviewed it for was ulcerative colitis.

Not tendon repair. Not shoulder pain. Not gym recovery. A bowel disease.

MOTS-c was reviewed for obesity and osteoporosis. Semax was reviewed for stroke, migraine, and trigeminal neuralgia. Epitalon was reviewed for insomnia.

If you have only ever heard these compounds discussed as recovery tools, that list should reframe how you think about them. The federal government did not evaluate these as fitness products. It evaluated them as medicine.

Here is what happened, what it actually changes, and the part almost nobody is reporting.

The FDA's Pharmacy Compounding Advisory Committee, called PCAC, met to decide whether seven peptides should be added to the 503A Bulk Drug Substances List.

That list is what allows a licensed compounding pharmacy to make a substance for you against a prescription.

The panel recommended six of the seven:

Emideltide, better known as DSIP, was the only one voted down.

The votes were close on all six. Most passed by a margin of two or three, with abstentions.

FDA's own scientific reviewers had recommended against listing all seven.

The panel went the other way on six of them.

That is unusual. Advisory committees often side with staff. This one did not, and the reasoning several members gave in the public record was straightforward: they wanted Americans getting these compounds from licensed pharmacies instead of unregulated overseas suppliers.

That is a legitimacy argument, and it is the same one this community has been making for years.

This is the official FDA agenda. These are the exact uses each substance was evaluated for.

Look at what is on that list. Gut disease. Bone density. Stroke recovery. Migraine. Sleep. Nerve pain. Opioid withdrawal.

Not one of those is a gym outcome.

Here is where it gets useful for you personally.

BPC-157 did not start as a tendon compound. It comes from a protein sequence found in human gastric juice. Its earliest research was digestive, which is exactly why FDA reviewed it for ulcerative colitis rather than rotator cuffs.

TB-500 is related to thymosin beta-4, a molecule present in many cell types throughout the body, which is why the review focused on wound healing broadly rather than muscle specifically.

MOTS-c being reviewed for osteoporosis is the one that should get your attention if you are over 40. Bone is living tissue, it remodels, and it is one of the first things to quietly decline. A compound most people file under "energy and metabolism" was serious enough on the bone side to reach a federal review docket.

Semax being reviewed for cerebral ischemia and migraine, not focus, tells you where the real clinical weight sits.

The pattern is consistent. The uses that made these compounds popular online are downstream of much broader biology. If you are only using them after a workout, you are using a fraction of what they were built around.

Be clear on this so you are not misled by headlines.

A PCAC vote is a recommendation. It is not a rule.

FDA leadership still has to decide whether to accept it, and then run a formal notice-and-comment rulemaking process to actually amend the list. That takes months, not days.

Nothing about your access changed on July 24.

Also worth knowing: appearing on the 503A list is not the same as FDA approval. It means a compounding pharmacy may legally prepare it for an individual patient. Those are two different things, and anyone telling you these peptides were just "approved" is skipping a step.

Go read the actual regulation, 21 CFR 216.23.

The 503A Bulks List currently contains six substances. Total. Things like Brilliant Blue G and cantharidin.

Six.

If FDA accepts these recommendations, six peptides would join a list that has six items on it. It would double in one action.

That is the scale of what was voted on last week, and it is why this landed in the Washington Post, NBC, NPR and Forbes in the same week.

A second PCAC meeting is expected before the end of February 2027.

Five more peptides are on that docket:

FDA has specifically indicated it plans to review GHK-Cu for noninjectable routes, which points toward oral and topical formats.

Mark that one. It matters for anyone running copper peptide capsules.

BioLongevity Labs is running 50% off sitewide, and today is the final day.

Sitewide 50% off, ends tonight Stack LEE15 at checkout for an extra 15% off on top of it.

That is the deepest combined discount they run all year, and it lands on the exact week these compounds got the biggest regulatory nod they have ever received.

If you have been building a stack around repair, sleep, brain, or metabolic support, this is the window.

An FDA advisory panel recommended six of seven peptides for legal compounding, going against the agency's own reviewers. Nothing has legally changed yet, and rulemaking still has to happen. The most interesting part is not the vote, it is the agenda: BPC-157 was reviewed for ulcerative colitis, MOTS-c for osteoporosis, Semax for stroke and migraine. These were evaluated as medicine, not gym supplements.

Talk soon,

Lee

Stop guessing. Start optimizing.

Free access to the stuff most people pay to learn

👉 Join the Free Group